Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>
<a href="https://smartkarma.com/entities/beone-medicines-ltd">BeOne Medicines</a> is rapidly transitioning into a commercial-stage global oncology powerhouse, driven by the strong performance of its flagship drug, BRUKINSA, which is gaining market share in various B-cell malignancies.</li>
 <li>The company has demonstrated a remarkable financial turnaround, achieving profitability in 2025 after years of significant investment in R&amp;D, underscored by an exponential revenue growth trajectory.</li>
 <li>With a deep and broad clinical pipeline of over 50 drug candidates, including more than 40 in clinical or commercial stages, the company is well-positioned for sustained long-term growth, though it faces intense competition and the inherent risks of biopharmaceutical development.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
BeOne Medicines is rapidly transitioning into a commercial-stage global oncology powerhouse, driven by the strong performance of its flagship drug, BRUKINSA, which is gaining market share in various B-cell malignancies.
  The company has demonstrated a remarkable financial turnaround, achieving profitability in 2025 after years of significant investment in R&amp;D, underscored by an exponential revenue growth trajectory.
  With a deep and broad clinical pipeline of over 50 drug candidates, including more than 40 in clinical or commercial stages, the company is well-positioned for sustained long-term growth, though it faces intense competition and the inherent risks of biopharmaceutical development.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: BeOne Medicines (6160 HK) - Aug 2026

<ul>
 <li>
<a href="https://smartkarma.com/entities/beigene-ltd-beone">BeOne</a> is rapidly transitioning into a profitable, commercial-stage biopharmaceutical company, driven by the blockbuster success of its BTK inhibitor, BRUKINSA, which generated $1.1 billion in sales in the first quarter of 2026.</li>
 <li>The company is demonstrating significant operating leverage, with a recent turn to GAAP net income and raised revenue guidance for FY26, signaling strong commercial execution and improving financial discipline.</li>
 <li>While heavily reliant on BRUKINSA, <a href="https://smartkarma.com/entities/beigene-ltd-beone">BeOne</a> possesses a deep and promising oncology pipeline with multiple near-term catalysts, including the recently approved BCL2 inhibitor Sonrotoclax and other assets, which could diversify revenue and sustain long-term growth.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
BeOne is rapidly transitioning into a profitable, commercial-stage biopharmaceutical company, driven by the blockbuster success of its BTK inhibitor, BRUKINSA, which generated $1.1 billion in sales in the first quarter of 2026.
  The company is demonstrating significant operating leverage, with a recent turn to GAAP net income and raised revenue guidance for FY26, signaling strong commercial execution and improving financial discipline.
  While heavily reliant on BRUKINSA, BeOne possesses a deep and promising oncology pipeline with multiple near-term catalysts, including the recently approved BCL2 inhibitor Sonrotoclax and other assets, which could diversify revenue and sustain long-term growth.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Healthcare Analyst

Wilfred Yuen

Thematic (Sector/Industry)

<ul>
<li>We highlight key updates from October's ESMO meeting: 1) Akeso's ivonescimab in 1L BTC, 2) Kelun/Merck's sac-TMT (Lung04, Lung06, TroFuse-005), 3) Hutchmed/AZ's savo, 4) Hansoh/GSK's B7H3 ADC, 5) Innovent IBI363...</li>
<li>BD deal flows this week: 1) Innocare/Lilly on 5-target drug discovery, 2) Earendil Labs/Genentech on bispecific, 3) Insilico Medicine/AI frontier model lab, 4) BoomRay/Novartis on radioligand, 4) Henlius/Amberstone on TCE</li>
<li>Other updates/news: 1) LEGN's 5-year Carvykti OS data in Cart-2 study, 2) BeOne's first-in-class GPC3/4-1BB entering ph3 study in HCC, 3) TYK/Qilu deal update...</li>
</ul>


We highlight key updates from October's ESMO meeting: 1) Akeso's ivonescimab in 1L BTC, 2) Kelun/Merck's sac-TMT (Lung04, Lung06, TroFuse-005), 3) Hutchmed/AZ's savo, 4) Hansoh/GSK's B7H3 ADC, 5) Innovent IBI363...
BD deal flows this week: 1) Innocare/Lilly on 5-target drug discovery, 2) Earendil Labs/Genentech on bispecific, 3) Insilico Medicine/AI frontier model lab, 4) BoomRay/Novartis on radioligand, 4) Henlius/Amberstone on TCE
Other updates/news: 1) LEGN's 5-year Carvykti OS data in Cart-2 study, 2) BeOne's first-in-class GPC3/4-1BB entering ph3 study in HCC, 3) TYK/Qilu deal update...


HK/China Equity Long-Short

Osbert Tang, CFA

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sichuan-kelun-biotech-biopharm" target="_blank" data-smartkarma-citation="entities:40071:1" rel="noopener">Sichuan Kelun-Biotech Bio (6990 HK)</a>, <a href="https://www.smartkarma.com/entities/techtronic-industries-co-ltd" target="_blank" data-smartkarma-citation="entities:4561:1" rel="noopener">Techtronic Ind. (669 HK)</a>, <a href="https://www.smartkarma.com/entities/vesync" target="_blank" data-smartkarma-citation="entities:31067:1" rel="noopener">Vesync (2148 HK)</a>, <a href="https://www.smartkarma.com/entities/chervon-holdings-limited" target="_blank" data-smartkarma-citation="entities:35309:1" rel="noopener">Chervon Hldgs (2285 HK)</a>, and <a href="https://www.smartkarma.com/entities/wuxi-apptec-co-ltd-bf4a1265-beef-48b6-b82d-29308426030f" target="_blank" data-smartkarma-citation="entities:27795:1" rel="noopener">WuXi AppTec (2359 HK)</a> have a very high reliance on the US market.</li>
<li>
<a href="https://www.smartkarma.com/entities/vtech-holdings-ltd" target="_blank" data-smartkarma-citation="entities:18812:1" rel="noopener">Vtech Hldgs (303 HK)</a>, <a href="https://www.smartkarma.com/entities/samsonite-international-sa" target="_blank" data-smartkarma-citation="entities:12790:1" rel="noopener">Samsonite (1910 HK)</a>, <a href="https://www.smartkarma.com/entities/haier-smart-home-co-ltd-b3ef445f-0f54-4586-8c58-9073de98d60e" target="_blank" data-smartkarma-citation="entities:31105:1" rel="noopener">Haier Smart Home (6690 HK)</a>, and <a href="https://www.smartkarma.com/entities/tcl-multimedia-technology" target="_blank" data-smartkarma-citation="entities:15654:1" rel="noopener">Tcl Multimedia (1070 HK)</a> ranked lower on the list, but consumer cutbacks will have a bigger impact. </li>
<li>The spillover effect of a US recession to other countries will pressurise companies that have low direct exposure, like <a href="https://www.smartkarma.com/entities/orient-overseas-international" target="_blank" data-smartkarma-citation="entities:801:1" rel="noopener">Orient Overseas International (316 HK)</a> and <a href="https://www.smartkarma.com/entities/prada-s-p-a" target="_blank" data-smartkarma-citation="entities:889:1" rel="noopener">Prada S.P.A. (1913 HK)</a>.</li>
</ul>



Sichuan Kelun-Biotech Bio (6990 HK), Techtronic Ind. (669 HK), Vesync (2148 HK), Chervon Hldgs (2285 HK), and WuXi AppTec (2359 HK) have a very high reliance on the US market.

Vtech Hldgs (303 HK), Samsonite (1910 HK), Haier Smart Home (6690 HK), and Tcl Multimedia (1070 HK) ranked lower on the list, but consumer cutbacks will have a bigger impact. 
The spillover effect of a US recession to other countries will pressurise companies that have low direct exposure, like Orient Overseas International (316 HK) and Prada S.P.A. (1913 HK).


China & HK Strategy: Who Are the Victims of a US Recession?

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>Hang Seng Indexes added three stocks in the May review. The first implementation week is complete, and we review current-cycle performance vs history.</li>
<li>All three ADDs fell in the first implementation week. The cohort averaged -4.1%, vs the historical ADD mean of -0.6%.</li>
<li>The pre-implementation base rates held for the two negative-bridge names. Weeks 2 to 4 then split the cohort: Chalco fell -26.6% while J&amp;T Express and BeOne Medicines rebounded.</li>
</ul>


Hang Seng Indexes added three stocks in the May review. The first implementation week is complete, and we review current-cycle performance vs history.
All three ADDs fell in the first implementation week. The cohort averaged -4.1%, vs the historical ADD mean of -0.6%.
The pre-implementation base rates held for the two negative-bridge names. Weeks 2 to 4 then split the cohort: Chalco fell -26.6% while J&amp;T Express and BeOne Medicines rebounded.


HSI June 2026 Index Rebalance: Post-Implementation Review

China

BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BeOne (ONC US)

Primer: BeOne Medicines (6160 HK) - Aug 2026

BeOne Medicines is rapidly transitioning into a commercial-stage global oncology powerhouse, driven by the strong performance of its flagship...

αSK Primers

Primer: BeOne (ONC US) - Aug 2026

BeOne is rapidly transitioning into a profitable, commercial-stage biopharmaceutical company, driven by the blockbuster success of its BTK...

αSK Primers

China Healthcare Weekly Wrap (21-25 Sep)

We highlight 1) key studies to watch for upcoming October's ESMO updates, 2) deal flows Innocare/Lilly, BoomRay/Novartis, Earendil Labs...

Wilfred Yuen

China & HK Strategy: Who Are the Victims of a US Recession?

Reliance on the US market varies among HK-listed companies, with some having high direct exposure to a recession. Those with low direct exposure...

Osbert Tang, CFA

HSI June 2026 Index Rebalance: Post-Implementation Review

HSI June 2026 rebalance has passed the first post-implementation week. We review what worked, what did not, and how current results compare with...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Primer: BeOne Medicines (6160 HK) - Aug 2026

BeOne Medicines is rapidly transitioning into a commercial-stage global oncology powerhouse, driven by the strong performance of its flagship...

αSK Primers

Primer: BeOne (ONC US) - Aug 2026

BeOne is rapidly transitioning into a profitable, commercial-stage biopharmaceutical company, driven by the blockbuster success of its BTK...

αSK Primers

China Healthcare Weekly Wrap (21-25 Sep)

We highlight 1) key studies to watch for upcoming October's ESMO updates, 2) deal flows Innocare/Lilly, BoomRay/Novartis, Earendil Labs...

Wilfred Yuen

China & HK Strategy: Who Are the Victims of a US Recession?

​Reliance on the US market varies among HK-listed companies, with some having high direct exposure to a recession. Those with low direct exposure...

Osbert Tang, CFA

HSI June 2026 Index Rebalance: Post-Implementation Review

HSI June 2026 rebalance has passed the first post-implementation week. We review what worked, what did not, and how current results compare with...

Ke Yan, CFA, FRM

Reliance on the US market varies among HK-listed companies, with some having high direct exposure to a recession. Those with low direct exposure...